Literature DB >> 18566754

CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

P P Scaglioni1, T M Yung, S Choi, S C Choi, C Baldini, G Konstantinidou, P P Pandolfi.   

Abstract

The PML tumor suppressor controls growth suppression, induction of apoptosis, and cellular senescence. PML loss occurs frequently in hematopoietic and solid tumors. PML loss often correlates with tumor progression. Casein kinase 2 (CK2) is a stress-activated serine/threonine protein kinase that is oncogenic and frequently overexpressed in human tumor of multiple histological origins. In addition, CK2 overexpression due to gene amplification has been reported to be an adverse prognostic factor in non-small cell lung cancer. At the 5th International Conference on Protein Kinase CK2 in Padova, Italy, we reviewed our recent findings that PML undergoes ubiquitin/proteasome-mediated degradation in immortalized and tumor derived cell lines. PML degradation depends on direct CK2 phosphorylation of PML Ser517. PML mutants that are resistant to CK2 phosphorylation display increased tumor suppressive functions in assays measuring apoptosis, replicative senescence, and in xenograft models. More significantly, CK2 pharmacological inhibition enhances PML tumor suppressive property. These data identify a key post-translational mechanism that controls PML protein levels in cancer cells and suggest that CK2 inhibitors may be beneficial anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566754     DOI: 10.1007/s11010-008-9812-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  41 in total

1.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

Review 2.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 3.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

4.  A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

Authors:  D M Keller; X Zeng; Y Wang; Q H Zhang; M Kapoor; H Shu; R Goodman; G Lozano; Y Zhao; H Lu
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

5.  Stress-induced activation of protein kinase CK2 by direct interaction with p38 mitogen-activated protein kinase.

Authors:  M Sayed; S O Kim; B S Salh; O G Issinger; S L Pelech
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

6.  Regulation of p53 activity in nuclear bodies by a specific PML isoform.

Authors:  V Fogal; M Gostissa; P Sandy; P Zacchi; T Sternsdorf; K Jensen; P P Pandolfi; H Will; C Schneider; G Del Sal
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

7.  Lack of expression for the suppressor PML in human small cell lung carcinoma.

Authors:  P Zhang; W Chin; L T Chow; A S Chan; A P Yim; S F Leung; T S Mok; K S Chang; P J Johnson; J Y Chan
Journal:  Int J Cancer       Date:  2000-03-01       Impact factor: 7.396

8.  Cytoplasmic PML function in TGF-beta signalling.

Authors:  Hui-Kuan Lin; Stephan Bergmann; Pier Paolo Pandolfi
Journal:  Nature       Date:  2004-09-09       Impact factor: 49.962

9.  Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389.

Authors:  Wendy Bruins; Edwin Zwart; Laura D Attardi; Tomoo Iwakuma; Esther M Hoogervorst; Rudolf B Beems; Barbara Miranda; Conny T M van Oostrom; Jolanda van den Berg; Gerard J van den Aardweg; Guillermina Lozano; Harry van Steeg; Tyler Jacks; Annemieke de Vries
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle.

Authors:  D C Seldin; P Leder
Journal:  Science       Date:  1995-02-10       Impact factor: 47.728

View more
  27 in total

1.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Authors:  Andreas Gratz; Uwe Kuckländer; Ricardo Bollig; Claudia Götz; Joachim Jose
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

3.  Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma.

Authors:  Nirojini Sivachandran; Christopher W Dawson; Lawrence S Young; Fei-Fei Liu; Jaap Middeldorp; Lori Frappier
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  PML: An emerging tumor suppressor and a target with therapeutic potential.

Authors:  Erin L Reineke; Hung-Ying Kao
Journal:  Cancer Ther       Date:  2009-09-01

Review 5.  Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

Authors:  Chandrika Gowda; Mario Soliman; Malika Kapadia; Yali Ding; Kimberly Payne; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2017-06-13

6.  A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.

Authors:  Madhuri Kalathur; Alberto Toso; Jingjing Chen; Ajinkya Revandkar; Claudia Danzer-Baltzer; Ilaria Guccini; Abdullah Alajati; Manuela Sarti; Sandra Pinton; Lara Brambilla; Diletta Di Mitri; Giuseppina Carbone; R Garcia-Escudero; Alessandro Padova; Letizia Magnoni; Alessia Tarditi; Laura Maccari; Federico Malusa; Ravi Kiran Reddy Kalathur; Lorenzo A Pinna; Giorgio Cozza; Maria Ruzzene; Nicolas Delaleu; Carlo V Catapano; Ian J Frew; Andrea Alimonti
Journal:  Nat Commun       Date:  2015-06-18       Impact factor: 14.919

7.  Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies.

Authors:  Nirojini Sivachandran; Jennifer Yinuo Cao; Lori Frappier
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

Review 8.  Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.

Authors:  Chandrika Gowda; Chunhua Song; Malika Kapadia; Jonathon L Payne; Tommy Hu; Yali Ding; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2016-09-18

9.  Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.

Authors:  Ming-Szu Hung; Yu-Ching Lin; Jian-Hua Mao; Il-Jin Kim; Zhidong Xu; Cheng-Ta Yang; David M Jablons; Liang You
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

10.  Identification of RNF168 as a PML nuclear body regulator.

Authors:  Kathy Shire; Andrew I Wong; Michael H Tatham; Oliver F Anderson; David Ripsman; Stephanie Gulstene; Jason Moffat; Ronald T Hay; Lori Frappier
Journal:  J Cell Sci       Date:  2015-12-16       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.